Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avience BiomedicalsNSE:AVIENCE +1.17%18 Gross Margin % is 40.17% as of Mar. 2025, which is 15% above its 10-year median of 34.95. GuruFocus rates NSE:AVIENCE with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 806 Medical Devices & Instruments companies, Avience Biomedicals ranks worse than 67.87% on this metric.
The historical rank and industry rank for Avience Biomedicals's Gross Margin % or its related term are showing as below:
NSE:AVIENCE'
s Gross Margin % Range Over the Past 10 Years
Min: 28.76 Med: 34.95 Max: 40.17
Current: 40.17
During the past 3 years, the highestGross Margin % of Avience Biomedicals was 40.17%. The lowest was 28.76%. And the median was 34.95%.
NSE:AVIENCE's Gross Margin % is ranked worse than 67.87% of 806
companies
in the Medical Devices & Instruments industry
Industry Median: 52.17
vs NSE:AVIENCE: 40.17
Avience Biomedicals had a gross margin of 40.17% for the quarter that ended in Mar. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Avience Biomedicals was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Avience Biomedicals had a gross margin of 40.17% for the quarter that ended in Mar. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Avience Biomedicals Gross Margin % Related Terms
Avience Biomedicals Gross Margin % Historical Data
* Premium members only.
The historical data trend for Avience Biomedicals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avience Biomedicals Gross Margin % Chart
Avience Biomedicals Annual Data
Trend
Mar23
Mar24
Mar25
Gross Margin %
28.76
34.95
40.17
Avience Biomedicals Semi-Annual Data
Mar23
Mar24
Mar25
Gross Margin %
28.76
34.95
40.17
NSE:AVIENCE vs ABT, SYK, MDT: Gross Margin % Comparison
For the Medical Devices subindustry, Avience Biomedicals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avience Biomedicals Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Avience Biomedicals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Avience Biomedicals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Avience Biomedicals (NSE:AVIENCE) has a Gross Margin % of 40.17% as of Mar. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Avience Biomedicals and its competitors. This is 15% above median its historical median of 34.95. Over the past decade, Avience Biomedicals' Gross Margin % has ranged from 28.76 to 40.17. According to the industry distribution chart, Avience Biomedicals ranks #547 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 67.9%.
Is Avience Biomedicals' Gross Margin % too high?
Avience Biomedicals' current Gross Margin % of 40.17% is 15% above median its 10-year median of 34.95. Over the past 10 years, this metric has ranged from a low of 28.76 to a high of 40.17. The Medical Devices & Instruments industry median Gross Margin % is 52.17. Avience Biomedicals' value of 40.17% is 23% below this industry median. Based on the distribution chart, Avience Biomedicals ranks #547 out of 806 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Avience Biomedicals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Avience Biomedicals ranks #547 out of 806 companies for Gross Margin %. This places Avience Biomedicals in the lower half of its industry. The industry median Gross Margin % is 52.17. Avience Biomedicals' value of 40.17% is 23% below this benchmark. Historically, Avience Biomedicals' own Gross Margin % has ranged from 28.76 to 40.17 over the past decade. While the company's 10-year median is 34.95 vs. the industry median of 52.17, Avience Biomedicals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.17, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avience Biomedicals's current Gross Margin % of 40.17% is 23% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Avience Biomedicals and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avience Biomedicals's current Gross Margin % is 40.17%, which is 15% above median its own 10-year median of 34.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current Gross Margin % of 40.17%. The current Gross Margin % is 40.17%, which is 15% above median its 10-year median of 34.95 and 23% below the Medical Devices & Instruments industry median of 52.17. Avience Biomedicals' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current Gross Margin % is 40.17% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
18GF Score
Get the complete analysis for NSE:AVIENCE
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AVIENCE has been successfully added to your 
